PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and the Flow Cytometry Facility at the Babraham Institute have announced a collaboration to develop a bespoke cell phenotyping...
Danish biotech company Vesper Bio has been awarded a grant worth $873,000 by The Michael J. Fox Foundation (MJFF) to assess sortilin inhibition in Parkinson’s disease.
Stimulants, amphetamines, and methylphenidates are currently the first-line treatment for moderate to severe attention-deficit/hyperactivity disorder (ADHD) across the seven major global markets; France, Germany, Italy, Spain, the UK, the US, and Japan....
Abzena, an end-to-end CDMO for biologics and bioconjugates, has launched AbZelect and AbZelectPRO cell line development (CLD) platforms to accelerate cell lie production for manufacturing antibodies and recombinant proteins.
The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has revealed that the UK has remained an attractive destination for commercial trials, with this type of clinical...
Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at approximately $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to be nearly $5 billion by 2032 in the seven major markets.
Oncology company Oxford BioTherapeutics has announced that the first patient has been dosed in a phase 1b trial investigating its lead candidate OBT076, in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck.
Tola Olorunnisola is currently senior vice president, clinical services & strategy at Avantor and along with her team is working on delivering digital innovations in the lab.
TrakCel, a provider of cellular orchestration systems to the cell and gene therapy (CGT) industry, has launched its own consultancy services to share its process development knowledge with the broader community of CGT developers.
Abbott and Tandem Diabetes Care recently announced the wireless integration of Abbott’s FreeStyle Libre 2 Plus continuous glucose monitor with the Tandem t:slim X2 insulin pump in the US.
CellVoyant, an AI-first biotechnology spin-out from the University of Bristol accelerating the development of novel cell therapies, has announced a £7.6 million seed round.
Sexual health pharmaceutical company Futura Medical has extended its exclusive licensing agreement with Cooper Consumer Health for the rights to commercialize its topical, gel-based erectile dysfunction treatment.
Following the news that AbbVie has launched Produodopa to treat severe motor fluctuations in patients with advanced Parkinson’s disease (PD) in the European Union (EU), Christine Wong, neurology analyst at GlobalData, offers her view:
Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has submitted an application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to...
Transgene and NEC are planning to extend their randomized phase 1 trial into a phase 2 study in 2024 to further demonstrate the potential of TG4050, a neoantigen vaccine for head and neck cancers.
We caught up with Kevin Knopp, CEO and co-founder of 908 Devices, to discuss the main obstacles in cell and gene therapy manufacturing and how the company's recent partnership with Terumo Blood and Cell Technologies is tackling these challenges.
Merck has announced a new licensing agreement with Inspirna for ompenaclid, a first-in-class treatment currently in phase 2 development for RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).
Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by data and analytics firm GlobalData.
AstraZeneca and Ionis have received FDA approval for Waiuna, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR).
Irish pharmaceutical company Shorla Oncology and consultancy firm Eversana have announced the U.S. launch of JYLAMVO, the first oral methotrexate solution.
Biotherapeutics company MediWound has secured an additional $6.7 million in funding from the US Department of Defense to advance its non-surgical burn treatment for the US Army.
At Veeva R&D and Quality Summit 2023, Bio Pharma Reporter caught up with Courtney Gilbert, senior director, business system management and innovation, PV operations and global process enablement, at Merck.
Antibody-drug conjugates (ADC) are booming in the biotech industry this year with mounting investment and M&A deals. Here are five ADC players that have caught the eye of investors in the last 12 months.
Hervé Affagard is the CEO and co-founder of MaaT Pharma and president of Alliance Promotion Microbiote. We sat down with him to discuss the company's promising lead product for gastrointestinal acute graft-versus-host disease.
A rising demand for biologics means that biotech companies face a multitude of manufacturing challenges, but also plenty of opportunities. We spoke to Kevin Sharp, senior VP and head of sales at Samsung Biologics, to examine what is driving this demand...
Novo Nordisk's Ozempic (semaglutide) took the weight loss sector by storm in 2023, propelled by strong efficacy and safety data, coupled with social media buzz and celebrity endorsements that elevated the drug to mainstream prominence.
Eligo Bioscience, a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures.
MaaT Pharma, a clinical-stage biotech company developing microbiome ecosystem therapies, has presented positive results from a recent study investigating its lead product MaaT013 for patients with steroid-refractory (SR) or steroid-dependent (SD) gastrointestinal...
Candel Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead adenovirus asset CAN-2409, for the treatment of pancreatic cancer.
UK-based Lindus Health and US-based Thirty Madison today (December 14) announced they have completed the enrolment of a trial to assess their personalized dermatology telemedicine platform, Facet.
Biotech company SolasCure has announced the results of its proof-of-concept phase 2 trial investigating its wound gel for chronic venous leg ulcer patients.
Biosenic, a company specializing in serious autoimmune and inflammatory diseases and cell therapy, has secured funding from Singapore-based TrialCap, in a bid to accelerate its phase 3 clinical development.
ViroCell Biologics, a London-based viral vector CDMO for cell and gene therapy clinical trials, has partnered with University College London (UCL) to advance its pediatric cancer treatment.
Skye Bioscience has announced its plans to develop nimacimab, the company’s monoclonal antibody recently acquired from Bird Rock Bio, for weight loss and the treatment of obesity.
Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation to support its vaccine development efforts.
Dr. Michael O’Neal, chief medical officer at Clario, believes that many drugs ultimately fail due to common operational and data challenges that could, and should, be corrected.
CASI Pharmaceuticals and Juventas Cell Therapy recently received approval from China's National Medical Products Administration (NMPA) for Yuanruida, a domestic CD19-targeting CAR-T therapy for relapsed/refractory B-Cell Acute Lymphocytic Leukemia.
Symbiosis Pharmaceutical Services can now test small molecule, biological and advanced therapeutical medicinal products (ATMP) following a £1 million investment.
Eli Lilly has invested in its manufacturing capacity once more and has announced plans to build a $2.5 billion high-tech manufacturing site in Germany.